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Abstract: BRAF and MEK kinase inhibitors can be highly effective in treating BRAF-mutant melanomas,
but their safety and activity in patients with active/symptomatic brain metastases are unclear. We
sought to shed light on this open clinical question. We conducted a multicenter retrospective study
on real-life patients with melanoma and active brain metastases treated with combination BRAF/MEK
inhibitors. A total of 65 patients were included (38 men and 27 women; median age: 49 years). Of
them, 53 patients received dabrafenib/trametinib, 10 received vemurafenib/cobimetinib, one received
encorafenib/binimetinib, and one received vemurafenib/trametinib. We did not observe any unexpected
treatment-related safety signals in our cohort. Overall, 17 patients continued on therapy through the
cutoff date. After initiation of therapy, steroid dose could be decreased in 22 of 33 patients (11 tapered
off entirely), anticonvulsants were stopped in four of 21, and narcotics were stopped in four of 12. Median
progression-free survival from the start of therapy was 5.3 months (95% confidence interval: 3.6-6.1), and
median overall survival was 9.5 months (95% confidence interval: 7.7-13.5). A total of 20 patients were
surviving at the cutoff date. Univariate analysis of age, sex, ulceration status, thickness, stage, location, or
lactate dehydrogenase did not reveal significant predictors of progression-free survival or overall survival
within our cohort, but multivariate analysis suggested that older age, lower risk location of original
lesion, and nodular melanoma are poor prognostic indicators. Combination therapy with BRAF/MEK
inhibitors is a viable treatment option for patients with BRAF-mutant melanoma and brain metastases,
but further studies should help to define the optimal treatment approach in this population.
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BRAF and MEK kinase inhibitors can be highly effective in
treating BRAF-mutant melanomas, but their safety and
activity in patients with active/symptomatic brain
metastases are unclear. We sought to shed light on this
open clinical question. We conducted a multicenter
retrospective study on real-life patients with melanoma and
active brain metastases treated with combination BRAF/
MEK inhibitors. A total of 65 patients were included (38 men
and 27 women; median age: 49 years). Of them, 53 patients
received dabrafenib/trametinib, 10 received vemurafenib/
cobimetinib, one received encorafenib/binimetinib, and one
received vemurafenib/trametinib. We did not observe any
unexpected treatment-related safety signals in our cohort.
Overall, 17 patients continued on therapy through the cutoff
date. After initiation of therapy, steroid dose could be
decreased in 22 of 33 patients (11 tapered off entirely),
anticonvulsants were stopped in four of 21, and narcotics
were stopped in four of 12. Median progression-free survival
from the start of therapy was 5.3 months (95% confidence
interval: 3.6–6.1), and median overall survival was
9.5 months (95% confidence interval: 7.7–13.5). A total of 20
patients were surviving at the cutoff date. Univariate
analysis of age, sex, ulceration status, thickness, stage,
location, or lactate dehydrogenase did not reveal significant
predictors of progression-free survival or overall survival
within our cohort, but multivariate analysis suggested that
older age, lower risk location of original lesion, and nodular
melanoma are poor prognostic indicators. Combination
therapy with BRAF/MEK inhibitors is a viable treatment
option for patients with BRAF-mutant melanoma and brain
metastases, but further studies should help to define the
optimal treatment approach in this population. Melanoma
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Introduction
Melanoma accounts for less than 1% of skin cancer diag-
noses but causes the overwhelming majority of skin cancer-
related deaths. The incidence of melanoma has risen over
the past 30 years, and estimates predicted more than 87 000
new cases and nearly 10 000 deaths occurred in 2017 in the
USA alone [1]. Treatment for many patients with invasive
melanoma was transformed with the discovery of mutations
in the BRAF gene, which occur in an estimated 50% of
cutaneous melanomas, and it drove cell growth and division
by the mitogen-activate protein kinase signaling pathway
[2]. Greater than 80% of BRAF mutations are caused by a
T1799A transversion in exon 15, resulting in the substitution
V600E (Val600Glu). Clinically, BRAF mutations are asso-
ciated with younger age, location of original lesion on the
trunk, lack of chronically sun-damaged skin, and aggressive
disease with advanced melanoma stage at presentation [3].
Among all cancers, melanoma is the third most common
cause of brain metastasis (after lung and breast) [4].
Approximately 7% of patients with melanoma are found to
have brain metastasis at diagnosis, and 40–50% of patients
with stage IV melanoma develop brain metastases at some
point in their disease course; indeed BRAF mutations may
predispose patients to developing brain metastases [5,6].
Brain involvement is associated with poor prognosis,
including an estimated 43% 3-month survival, as well as a
high degree of morbidity and cost [7].
Several therapies targeting BRAF are currently in use or
under investigation for the treatment of BRAF-mutant
metastatic melanoma, including vemurafenib [approved
by the Food and Drug Administration (FDA) in 2011],
dabrafenib (FDA approved in 2013), and encorafenib
(FDA approval pending) [8–10]. More recently, BRAF
inhibitors are co-administered with inhibitors of MEK,
Original article 65
0960-8931 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/CMR.0000000000000527
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
another kinase downstream of BRAF in the same sig-
naling pathway. Combination therapy of BRAF inhibitors
with the MEK inhibitors trametinib (FDA approved in
2013), cobimetinib (FDA approved in 2015), and bini-
metinib (FDA approval pending), improves survival over
monotherapy with BRAF inhibitors alone [11–14].
The clinical development of BRAF inhibitors with or
without MEK inhibitors was largely limited to patients
who did not have active brain metastases, and thus the
role of BRAF-targeted therapy in patients with brain
metastases is not yet fully understood. One other recent
retrospective study showed a median overall survival of
6.6 months, median intracranial progression-free survival
(PFS) of 4.2 months, and intracranial radiologic response
rate of 63% for patients with symptomatic brain metas-
tases [15]. Early-phase trials show promising signs of
intracranial efficacy, including response rates of 20–40%
with dabrafenib, and 40% with vemurafenib; ongoing
prospective trials are just beginning to reach the literature
[16–18]. For example, the COMBI-MB study recently
prospectively investigated the use of dabrafenib plus
trametinib in patients with melanoma and brain metas-
tases, finding a median PFS of 5.6 months, and a median
overall survival (OS) of 10.8 months [19]. However,
prognostic data from clinical trials may not be perfectly
representative owing to selection bias in trial participants
[20]. To contribute to the developing data on this patient
population, we present our multicenter experience
treating real-life patients with melanoma brain metastases
with combination BRAF/MEK-inhibitor therapy.
Patients and methods
The objective of this study was to characterize the clin-
ical course of patients with BRAF-mutated metastatic
melanoma and brain metastases who received combina-
tion BRAF and MEK targeted therapy (BRAF/MEK-I).
To merit inclusion, patients were required to have
biopsy-proven melanoma with brain metastases harbor-
ing a BRAF mutation at the V600 position, and to have
received combination BRAF/MEK-I therapy between
2013 and the data cutoff date of 25 October 2016, at one
of our five clinical centers. Retrospective chart review
was performed on all patients to obtain data concerning
features of patients’ initial melanoma diagnosis, sympto-
matic response to therapy, treatment interruptions/
adverse events, time to progression, and overall survival.
Statistical analysis
Demographic and disease characteristics, patient status,
and treatment are summarized descriptively. OS is
defined as the time from the start of BRAF inhibitor to
death from any cause, and patients who did not die are
censored at the date last known alive. PFS is defined as
the time from the start of BRAF inhibitor to progression
or death from any cause, and patients who did not pro-
gress or die are censored at the date last known alive.
Several patients started combination therapy in a stag-
gered fashion, starting with BRAF inhibitor before the
initiation of a MEK inhibitor. This occurred when access
to trametinib was limited to compassionate use at
European sites. The distributions of survival are pre-
sented using the method of Kaplan–Meier along with the
95% confidence interval (CI). The 95% CI of the median
survival times are estimated using log[− log(endpoint)]
methodology. Multivariable Cox models are fit using
backward, forward, and stepwise selection to assess
model consistency. Candidate predictors in the models
are age (divided at 49 years), Breslow thickness (0.1–2,
2.01–4, > 4 mm, and unknown), ulceration (no, yes, and
unknown), location (higher risk, lower risk, other, and
unknown), type of melanoma (superficial spreading,
nodular, other, and unknown), and lactate dehydrogenase
at treatment start (normal, abnormal, and unknown).
Hazard ratios are presented with 95% Wald CIs.




We identified 65 patients who met the inclusion criteria
for the analysis. Of them, 26 (40.0%) were treated at
Massachusetts General Hospital, 25 (38.5%) were treated
at Essen, 10 (15.4%) were treated at Zurich, two (3.1%)
were treated at St Gallen, and two (3.1%) were treated at
Basel. The median (95% CI) follow-up duration was 19
(16–31) months. Demographic data are summarized in
Table 1.
Treatment regimens and previous therapies
A total of 53 (81.5%) patients received dabrafenib/tra-
metinib, 10 (15.4%) received vemurafenib/cobimetinib,
one received encorafenib and binimetinib, and one
received vemurafenib and trametinib. Forty-four (67.7%)
patients received systemic therapy before the initiation of
BRAF/MEK inhibitors. Twelve (18.5%) patients started
combination therapy in a staggered fashion, starting with
BRAF inhibitor a median of 16.5 days before the initia-
tion of a MEK inhibitor. Eighteen (27.7%) had received
before anti-CTLA-4 therapy, 12 (18.5%) received before
anti-PD1 therapy, 13 (20%) received previous adjuvant
interferon, and three (4.6%) received previous che-
motherapy. Eighteen (27.7%) underwent brain surgery
before the treatment start, 22 (33.8%) underwent ste-
reotactic radiosurgery, and 20 (33.3%) underwent whole-
brain radiation.
Treatment toxicity and adverse events
Seventeen (26.2%) patients remained on therapy through
data cutoff date. Seven (10.8%) patients required dose
reductions, six of which were because of fever. Twenty-
two (33.8%) patients had treatment interruptions, which
lasted for an average of 23.5 days. Interruption occurred
owing to fever [14 (63.6%) interruptions], radiation
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therapy (n= 4), infection (n= 2), and hepatitis/abnormal
liver function tests (n= 2). Forty-eight (73.8%) patients
discontinued therapy entirely, 33 (68.8% of discontinua-
tions) because of disease progression, and 10 (20.8%)
because of adverse events. Of the 10 patients who stop-
ped therapy owing to adverse events, fever was the
principal reason in eight cases, and abnormal liver func-
tion tests accounted for the other two.
In the overall study population, the most common adverse
event was fever, which occurred in 13 (20%) patients. Nine
(13.8%) patients had a rash, seven (10.8%) had fatigue, six
(9.2%) had CK elevation/myositis, six (9.2%) had infection,
five (7.7%) had diarrhea, four (6.2%) had abnormal liver
function tests, three (4.6%) had fevers, three (4.6%) had
thrombosis, two (3.1%) had palpitations, two (3.1%) had
nausea, and two (3.1%) had hypertension. Only one patient
experienced each of the following: ocular complications,
dizziness, alopecia, central nervous system bleed, and
myocardial infarction.
Symptomatic response
The most common neurologic symptoms that patients
noted at baseline were headaches [18 (27.7%)] and motor
symptoms such as paralysis [18 (27.7%)]. Ten (15.4%)
had a documented history of sensory disturbance, and
seven (10.8%) had seizures. Thirty-three (50.8%) patients
were taking steroids at the start of BRAF inhibitor ther-
apy, of which 22 (66.7% of those on steroids) were able to
decrease their steroid dose after starting therapy, and 11
(33.3% of those on steroids) were able to taper off ster-
oids. Twenty-one (32.3%) were taking anticonvulsants at
treatment start, and four (19% of those on antic-
onvulsants) tapered off therapy. Twelve (18.5%) were
taking narcotic pain medications at treatment start, and
four (33.3% of those on narcotics) could discontinue after
treatment commencement (Table 2).
Survival analyses
At the data cutoff date, 57 (87.7%) patients exhibited
disease progression, and 45 (69.2%) patients had died.
Median progression-free survival from start of BRAF/
MEK inhibitor was 5.3 months (95% CI: 3.6–6.1).
Median overall survival from start of BRAF/MEK inhi-
bitor therapy was 9.5 months (95% CI: 7.7–13.5), as
shown in Figs 1 and 2. Univariate analysis of all pre-
sented demographic variables did not reveal significant
predictors of survival within our cohort.
Multivariate analysis revealed that overall survival was
significantly related to age, location, and type of melan-
oma. Holding other predictors constant, patients older
than 49 years had hazards of death that were more than
Table 1 Baseline patient characteristics
Characteristics n (%)





European cohort 39 (60)
American cohort 26 (40)
UICC-stage at first diagnosis
Breslow ≤2mm 16 (24.6)
2–4mm 16 (24.6)
LN or in transit 15 (23.1)
Distant mets 15 (23.1)
Unknown 3 (4.6)
Location of primary lesion
Lower risk (upper or lower extremity) 12 (18.5)






















BRAF/MEK-I, BRAF/MEK inhibitor; LDH, lactate dehydrogenase; LN, lymph
nodes; max, maximum; min, minimum.
Table 2 Clinical outcomes
Outcomes n (%)
Steroid response
Taking steroids at treatment start 33
Steroid dose reduction after treatment 22 (66.7)
Steroid discontinuation after treatment 11 (33.3)
Anticonvulsant response
Taking anticonvulsants at treatment start 21
Anticonvulsant dose reduction after treatment 4 (19)
Anticonvulsant discontinuation after treatment 0 (0)
Opioid response
Taking opioids at treatment start 12
Opioid dose reduction after treatment 4 (33)
Opioid discontinuation after treatment 4 (33)




CK elevation/myositis 6 (9.2)
Infection 6 (9.2)
LFT abnormalities/hepatitis 4 (6.2)
Therapy discontinuation
Total discontinuation events 48
Discontinuation due to progression of disease 33 (68.8)
Discontinuation due to adverse event 10 (20.8)
Other 5 (10.4)
Mortality at study close
Alive 20 (30.8)
Dead 45 (69.2)
Progression at study close
No progression 7 (10.8)
Progression 57 (87.7)
Unknown 1 (1.5)
CK, creatine kinase; LFT, liver function test.
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double those of patients younger than 49 years [hazard
ratio (HR): 2.18, 95% CI: 1.09–4.37; P= 0.03]. The
hazards of death for patients with lower risk location
(upper or lower extremity) increased more than three
times (HR: 3.32, 95% CI: 1.48–7.46; P= 0.01) compared
with patients with higher risk location (head/neck or
torso) while holding other covariates constant. Finally,
the hazards of death for patients with nodular melanoma
increased almost five times (HR: 4.95, 95% CI:
1.92–12.75; P= 0.01) compared with patients with
spreading melanoma while holding other covariates
constant.
Discussion
Targeted therapy with BRAF/MEK inhibitors is a fea-
sible treatment paradigm and alternative to immu-
notherapy in patients with BRAF-mutant melanoma with
brain metastases. Despite that, the presence of brain
metastases in metastatic melanoma is still a devastating
diagnosis with a median PFS of 5.3 months, and a median
OS of 9.5 months in our cohort. Our results align closely
with the prospective COMBI-MB trial that reported a
median PFS of 5.6 months and a median OS of
10.8 months for patients taking dabrafenib plus trameti-
nib for BRAF-mutant melanoma with brain metas-
tases [19].
We observed a treatment-related steroid dose reduction
in two-third of those patients taking steroids at therapy
induction, about half of whom were able to discontinue
steroids entirely. A similar trend was noted in the
reduction/discontinuation of anticonvulsants and narcotic
pain medication. We did not measure intracranial
response directly, but note that in the COMBI-MB study
population, intracranial response rates were largely
equivalent to (if not better than) extracranial response
rates [19]. Although our findings represent an imperfect
surrogate for intracranial response, they suggest con-
cordance with the COMBI-MB data, and may help to
allay doubts that still exist about the ability of these drugs
to successfully penetrate the central nervous system
[21–23].
A screen of available baseline patient characteristics did
not reveal any univariate predictors of PFS or OS in our
cohort, but multivariate analysis suggested older age,
lower risk location of original lesion, and nodular
melanoma to be poor prognostic indicators. This study
was not designed for predictive modeling, and these
results should be interpreted with care unless validated
in a larger cohort.
We report a toxicity profile that reflects previous reports
in the literature, with fever, rash, myositis, diarrhea, and
infections accounting for most adverse events [24].
Our population was heterogeneous, international, heavily
pretreated, and included patients with significant medical
co-morbidities. This increases the real-world applicability
and generalizability of the results. However, the study
was retrospective, nonrandomized, and uncontrolled,
therefore unable to provide insight into the relative
Fig. 2
Overall survival (OS). Median overall survival from start of BRAF/MEK-
inhibitor therapy was 9.5 months (95% confidence interval: 7.7–13.5).
Fig. 1
Progression-free survival (PFS). Median progression-free survival from
start of BRAF/MEK-inhibitor was 5.3 months (95% confidence interval:
3.6–6.1).
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efficacy of any particular BRAF/MEK-inhibitor regimen,
or compare BRAF/MEK-inhibitors to alternative therapy
strategies.
Given the prevalence of brain metastases and BRAF
mutations in metastatic melanoma, further studies are
needed to compare the relative efficacy of available
BRAF/MEK-I regimens in this population. In particular,
data on the use of vemurafenib/cobimetinib are lacking.
Beyond that, it is still unknown whether BRAF/MEK-I
should be used alongside or in parallel with brain radia-
tion and/or immunotherapy for patients with brain
metastases. It is also unknown how pretreatment with
immunotherapy could influence response to targeted
therapy, or vice-versa. We hope that further studies can
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